Presentation is loading. Please wait.

Presentation is loading. Please wait.

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.

Published byTodd Austin Modified over 9 years ago

Similar presentations

Presentation on theme: "PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering."— Presentation transcript:

1 PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS May 24, 2010 National Cancer Institute

2 Industry/Commercial 1.Astra-Zeneca 2.Merck 3.Genentec 4.McKesson 5.NavigatingCancer.com

3 Cooperative Group Trials 1.CALGB 360901: Memantine as neuroprotector for PCI in SCLC (Ahles) 2.NCCTG 0949/CALGB 81002: FOLFOX/Bev vs. Fluoropyrimidine/Bev in metastatic colorectal cancer in older patients (Jackson, Grothey) 3.CALGB 80903: Ph3 chemo +/- liver cytoreduction in liver metastasis-dominant colorectal cancer (Solomon/Zafar) 4.CALGB 80702: Ph3 adjuvant FOLFOX + celecoxib or placebo in resected stage III colon cancer (Meyerhardt/Shields) 5.SWOG XXX: Diarrhea evaluation (Monipoor) 6.CALGB 81001: Ph2 neoadjuvant FOLFOX +/- RT in good-risk rectal cancer (Schrag) 7.RTOG 1016: Favorable risk H/N cancer (Trotti/Ringash)

4 Academic 1.DFCI: Lung cancer symptoms (Cooley R01) 2.University of Tokyo: Japanese translation (Kuroda/Yamaguchi) 3.MSKCC: Oropharynx cancer longitudinal QOL (Baxi/Pfister) 4.Johns Hopkins: Patient preferences in lung cancer (Bridges)

Download ppt "PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering."

Similar presentations

Diagnosis.

Diagnosis.
Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics Memorial.

Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics Memorial.
Advances and Emerging Therapy for Lung Cancer

Advances and Emerging Therapy for Lung Cancer
Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.
PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,
TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee September 17, 1999.

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee September 17, 1999.
Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Cancer Center Trials at St. Barnabas Medical Center.

Cancer Center Trials at St. Barnabas Medical Center.
Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.
Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.

Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.
ACRIN 6657/CALGB 150007 Consent for Research Study Contrast-Enhanced Breast MRI and MRS: A Correlative Science Studies to Characterize Tumor Response in.

ACRIN 6657/CALGB Consent for Research Study Contrast-Enhanced Breast MRI and MRS: A Correlative Science Studies to Characterize Tumor Response in.
Colorectal Cancer Center Jena 18.05.2011 Introduction In Germany, there are currently approximately 70 000 newly diagnosed patients with colorectal carcinoma.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Pharmacogenomics: Studies in Breast Cancer Lynn C. Hartmann MD Mayo Clinic Cancer Center.

Pharmacogenomics: Studies in Breast Cancer Lynn C. Hartmann MD Mayo Clinic Cancer Center.

Similar presentations

Ads by Google